Does 1+1= 80m patients ?
( an LL / Absci collab sure seems to fit.
Including throwing in their Ai for our inflammation path )
Alopecia areata (AA) is a non-scarring inflammatory hair loss disorder characterized by a T-cell–mediated autoimmune disease that targets the hair follicles. In particular, Natural Killer Group 2 member D (NKG2D)+CD8+ T cells have been identified as central players in its pathogenesis.
Current treatment options have limited efficacy and are often associated with adverse effects and high risk of relapse upon discontinuation, highlighting the need for targeted and durable therapeutic strategies.
Janus kinase (JAK) inhibitors have emerged as representative therapies; however, they are limited by a high relapse rate after treatment cessation.
Recently, novel therapeutic approaches such as neutralizing antibodies targeting cytokines and chemokines, and sphingosine-1-phosphate (S1P) receptor modulators have gained attention.
Various molecular markers associated with AA have been identified as potential therapeutic targets.
______
Now look @ 1 of ABSCI's direct focus:
Alopecia as trial ABS-201
Website says 80m living with Alopecia
https://www.absci.com/our-pipeline/
A random 2025 abstract on Alopecia:
https://www.frontiersin.org/journals/immunolo...81163/full
Redmile Group & Absci:
https://stocktwits.com/my69z/message/649779958
( an LL / Absci collab sure seems to fit.
Including throwing in their Ai for our inflammation path )
Alopecia areata (AA) is a non-scarring inflammatory hair loss disorder characterized by a T-cell–mediated autoimmune disease that targets the hair follicles. In particular, Natural Killer Group 2 member D (NKG2D)+CD8+ T cells have been identified as central players in its pathogenesis.
Current treatment options have limited efficacy and are often associated with adverse effects and high risk of relapse upon discontinuation, highlighting the need for targeted and durable therapeutic strategies.
Janus kinase (JAK) inhibitors have emerged as representative therapies; however, they are limited by a high relapse rate after treatment cessation.
Recently, novel therapeutic approaches such as neutralizing antibodies targeting cytokines and chemokines, and sphingosine-1-phosphate (S1P) receptor modulators have gained attention.
Various molecular markers associated with AA have been identified as potential therapeutic targets.
______
Now look @ 1 of ABSCI's direct focus:
Alopecia as trial ABS-201
Website says 80m living with Alopecia
https://www.absci.com/our-pipeline/
A random 2025 abstract on Alopecia:
https://www.frontiersin.org/journals/immunolo...81163/full
Redmile Group & Absci:
https://stocktwits.com/my69z/message/649779958
3
